FAR10

FAR10 is a small molecule androgen receptor (AR) antagonist belonging to a series of 4,4-dimethylimidazolidin-2-one pharmacophore-based compounds (FAR01-FAR11). It was designed as a flexible analog of second-generation AR antagonists, such as enzalutamide, by replacing the rigid thiohydantoin ring with a flexible 4,4-dimethylimidazolidin-2-one moiety and introducing a methylene spacer to enhance conformational flexibility. FAR10 is intended for the treatment of prostate cancer, including castration-resistant prostate cancer (CRPC), by inhibiting AR signaling, which remains a primary driver of tumor growth even under androgen deprivation therapy. The compound has been evaluated in vitro using androgen-dependent LNCaP prostate cancer cell lines to determine its potency relative to established therapies.